Discordant rifampicin susceptibility results are associated with Xpert(®) MTB/RIF probe B and probe binding delay

Por Berhanu, R. H., Schnippel, K., Kularatne, R., Firnhaber, C., Jacobson, K. R., Horsburgh, C. R., Lippincott, C.K.
Publicado no Int J Tuberc Lung Dis (2019)

Discordant rifampicin susceptibility results are associated with Xpert® MTB/RIF probe B and probe binding delay

Por Berhanu, R. H., Schnippel, K., Kularatne, R., Firnhaber, C., Jacobson, K. R., Horsburgh, C. R., Lippincott, C.K.
Publicado no Int J Tuberc Lung Dis (2019)

Overcoming limitations of tuberculosis information systems: researcher and clinician perspectives

Por van der Heijden, Y. F., Hughes, J., Dowdy, D. W., Streicher, E., Chihota, V., Jacobson, K. R., Warren, R., Theron, G.
Publicado no Public Health Action (2019)

The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis

Por Ragan, E. J., Kleinman, M. B., Sweigart, B., Gnatienko, N., Parry, C. D., Horsburgh, C. R., LaValley, M. P., Myers, B., Jacobson, K. R.
Publicado no Int J Tuberc Lung Dis (2020)

Rise in rifampicin-monoresistant tuberculosis in Western Cape, South Africa

Por Mukinda, F. K., Theron, D., van der Spuy, G. D., Jacobson, K. R., Roscher, M., Streicher, E. M., Musekiwa, A., Coetzee, G. J., Victor, T. C., Marais, B. J., Nachega, J. B., Warren, R. M., Schaaf, H. S.
Publicado em 2012